By clicking on the “Calculate” button below, you acknowledge that you have read, understand, and agree to be bound by the terms of the QxMD Online Calculator End User Agreement.
Use this calculator to determine prognosis in Diffuse Large B-cell Lymphoma using the Revised International Prognostic Index (R-IPI).
*ECOG: Eastern Cooperative Oncology Group scale, in which 0 indicates that the patient has no symptoms, 1 indicates the patient has symptoms but is ambulatory, and 2 indicates the patient is bedridden less than half the day, 3 indicates the patient is bedridden half the day or longer, and 4 indicates the patient is chronically bedridden and requires assistance with the activities of daily living.
About this calculator
The original International Prognostic Index (IPI) was developed and validated prior to the addition of rituximab to curative anthracycline-based chemotherapy. Clinical trials have confirmed that rituximab improves the survival of individuals with diffuse large B-cell lymphoma. The revised International Prognostic Index (R-IPI) was developed to predict the outcome of individuals receiving rituximab with chemotherapy. The score is able to differentiate patients into three groups (very good, good, poor), all of whom have survival > 50% in the new era.
The original IPI was developed by Shipp et al. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. NEJM 329:987-994. (1993)
The newer prognostic index was revised and developed by Sehn et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861. (2007)
QxMD Hematology contributing author: Dr. Matthew Cheung, MD, SM, FRCP(C)